These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://monicazltf266134.bcbloggers.com/38034407/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide